IP Law 360

OCTOBER 15, 2021

million) claim against Boehringer Ingelheim International GmbH, finding the patent licensing company did not change the basis on which it can collect royalties in bad faith. A London judge has sided with Royalty Pharma in its €23 million ($26.6

Licensing 52

Licensing Patent 52

SpicyIP

MARCH 8, 2022

Earlier, in 2002, in Glaxo Smith Kline – Boehringer Ingelheim Case (which is regarding the excessive pricing of HIV drugs), the Competition Commission found the companies to have charged excessive prices. The South African Competition Act perceives unreasonable excessive pricing as an element of abuse of dominance.

Marketing 119

Marketing Marketing 119

Bio Law Blog

JANUARY 8, 2020

However, for the past two years, Boehringer Ingelheim has been conducting interchangeability studies for a biosimilar to AbbVie’s Humira. On March 18, 2019, an antitrust class action lawsuit was filed by a welfare fund against AbbVie and seven biosimilar companies involving the drug adalimumab (Humira).

Marketing 40

Marketing Marketing Settlement Litigation 40

SpicyIP

NOVEMBER 28, 2023

Controller of Patents (2023), differed with the findings of a coordinate bench in Boehringer Ingelheim v. Setting the Criteria for Divisional Applications: Boehringer Ingelheim v. Later in the Boehringer Ingelheim case , the applicant submitted a PCT national phase application with 18 separate claims.

Invention 59

Invention Patent Application Patent Intellectual Property 59

Fish & Richardson Trademark & Copyright Thoughts

MARCH 8, 2021

Around that same time, FDA responded to Pfizer’s August 2018 citizen petition in which the company asked the agency to issue guidance “to ensure truthful and non-misleading communications by sponsors concerning the safety and effectiveness of biosimilars, including interchangeable biologics, relative to reference product(s).”

Settlement 40

Settlement Licensing Designs Design 40

SpicyIP

SEPTEMBER 15, 2023

Apparently filing sparse basic details once in three years may also be too much of a burden for innovative companies, so the rules also propose that the Controller be given the power to condone delays upon payment of some fees. Previously, in Boehringer Ingelheim v. Controller of Patents and Anr.

Patent 105

Patent Invention Public Domain Patent Application 105

SpicyIP

OCTOBER 16, 2023

Image from here Raytheon Company v. Relying on the language of Section 16, the division bench overruled the Boehringer Ingelheim order and held that a divisional application will be maintainable provided the plurality of application is disclosed in the provisional or complete specification. Tejaswini writes on this development.

Due Diligence 59

Due Diligence Invention IP Copyright 59